Treatment characteristics of fully vaccinated patients with MM by breakthrough infection status
| . | Overall . | Breakthrough infection . | P value . | |
|---|---|---|---|---|
| Yes . | No . | |||
| Full cohort | 1822 | 180 (9.9) | 1642 (90.1) | |
| Treatment timing∗ | ||||
| Within 90 d | 1413 | 159 (11.3) | 1254 (88.7) | <.001 |
| 90 to 180 d | 159 | 8 (5.0) | 151 (95.0) | .045 |
| >180 d | 250 | 13 (5.2) | 237 (94.8) | .011 |
| Treatment type† | ||||
| IMiD | 1352 | 149 (11.0) | 1203 (89.0) | .007 |
| Proteasome inhibitor | 1035 | 129 (12.5) | 906 (87.5) | <.001 |
| Chemotherapy | 566 | 66 (11.7) | 500 (88.3) | .104 |
| Anti-CD38 | 399 | 65 (16.3) | 334 (83.7) | <.001 |
| Other | 49 | 9 (18.4) | 40 (81.6) | .076 |
| . | Overall . | Breakthrough infection . | P value . | |
|---|---|---|---|---|
| Yes . | No . | |||
| Full cohort | 1822 | 180 (9.9) | 1642 (90.1) | |
| Treatment timing∗ | ||||
| Within 90 d | 1413 | 159 (11.3) | 1254 (88.7) | <.001 |
| 90 to 180 d | 159 | 8 (5.0) | 151 (95.0) | .045 |
| >180 d | 250 | 13 (5.2) | 237 (94.8) | .011 |
| Treatment type† | ||||
| IMiD | 1352 | 149 (11.0) | 1203 (89.0) | .007 |
| Proteasome inhibitor | 1035 | 129 (12.5) | 906 (87.5) | <.001 |
| Chemotherapy | 566 | 66 (11.7) | 500 (88.3) | .104 |
| Anti-CD38 | 399 | 65 (16.3) | 334 (83.7) | <.001 |
| Other | 49 | 9 (18.4) | 40 (81.6) | .076 |
IMiD, immunodulatory imide drugs.
Defined on the basis of the date of last dose of systemic antimyeloma therapy received before the third vaccine dose.
Defined on the basis of all systemic antimyeloma therapies received within 90 days before the third vaccine dose. Patients who received multiple treatment types in this time period are included in multiple treatment type categories.